Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nonprescription Office In Transition Works To Hire Division Heads

This article was originally published in The Tan Sheet

Executive Summary

Filling the posts of division directors is the current primary focus for Office of Nonprescription Products Director Charles Ganley, MD
Advertisement

Related Content

ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
Actual Use, Label Comprehension Guidances Slated For 2006
Actual Use, Label Comprehension Guidances Slated For 2006
Actual Use, Label Comprehension Guidances Slated For 2006
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches
FDA Rx-To-OTC MaPP On Course For Release In 2005

Topics

Advertisement
UsernamePublicRestriction

Register

PS098873

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel